Author Index: J

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jacob, I.
• COST-EFFECTIVENESS OF RISK-BASED STRATIFIED BREAST CANCER SCREENING
Jacobs, P.
• WHEN, WHY, AND FOR WHOM ARE NATURAL FREQUENCY FORMATS MOST EFFECTIVE? A META-ANALYSIS

• ESTIMATING THE BENEFIT OF A NATIONAL PROVISION OF COCHRANE REVIEWS
Jacobsen, R. L.
• DIAGNOSING QUALITY OF TREATMENT FROM SURVIVAL TIMES
Jacobson, J. P.
• DOMINANT ASPIRIN THERAPY STRATEGY ELIMINATES ROLE FOR IMAGING SCREENING/WARFARIN THERAPY FOR STROKE PREVENTION IN MODEL OF ASYMPTOMATIC BLUNT NECK TRAUMA
Jahn, B.
• CLOSING CEREMONY AND AWARD PRESENTATIONS

• BUDGET IMPACT ANALYSIS INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C IN FRANCE

• AN OVERVIEW OF DIFFERENT MAPPING TECHNIQUES TO DERIVE HEALTH STATE UTILITY VALUES IN MULTIPLE MYELOMA FOR DECISION-ANALYTIC MODELING

• SMDM CORE COURSE: INTRODUCTION TO MEDICAL DECISION ANALYSIS (DECISION-ANALYTIC MODELING)
Janes, S.
• PREDICTORS OF PATIENT PREFERENCES FOR WHOLE BODY MAGNETIC RESONANCE IMAGING COMPARED WITH STANDARD STAGING PATHWAYS FOR THE INVESTIGATION OF SYMPTOMS OF SUSPECTED COLORECTAL OR LUNG CANCER
Janssen, M.
• DECISION MAKING AND VALUE OF INFORMATION ANALYSIS IN A REAL-WORLD MULTI-CRITERIA CONTEXT
Jansson-Knodell, C.
• INCREASING HIGH-VALUE VENOUS THROMBOEMBOLISM PROPHYLAXIS: A WIN-WIN SITUATION
Jeanblanc, G.
• DIRECT ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 OR 4 IN FRANCE - COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR BY FIBROSIS SUBGROUP

• BUDGET IMPACT ANALYSIS INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C IN FRANCE
Jelonek, A.
• CONSTRAINTS, CAPACITY AND CAPABILITY: AN APPLICATION OF MATHEMATICAL OPTIMISATION METHODS
Jenny, M. A.
• ORAL ABSTRACTS: RISK PERCEPTION AND COGNITIVE BIASES

• IMPROVING MEDICAL DECISIONS WITH COGNITIVE DATA SCIENCE
Jevdjevic, M.
• AN OVERVIEW OF DIFFERENT MAPPING TECHNIQUES TO DERIVE HEALTH STATE UTILITY VALUES IN MULTIPLE MYELOMA FOR DECISION-ANALYTIC MODELING

• COSTS OF FIRST-LINE TREATMENT FOR ELDERLY MULTIPLE MYELOMA PATIENTS WHO ARE NOT TRANSPLANT CANDIDATES IN THE SERBIAN HEALTH CARE SYSTEM

• META-ANALYSIS AND INDIRECT TREATMENT COMPARISON OF SAFETY PROFILES OF BORTEZOMIB- AND THALIDOMIDE-BASED REGIMENS FOR THE FIRST LINE TREATMENT OF ELDERLY TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA
Jha, V.
• UNDERSTANDING DOCTORS' PERCEPTIONS OF GOOD CLINICAL DECISION MAKING: AN INTERVIEW STUDY
Joeris, A.
• DO SURGERY JOURNALS REPORT RISK REDUCTION INFORMATION IN A WAY THAT COULD PROMOTE BIAS?
Johnson, M.
• CONVEYING UNCERTAINTY ABOUT PRICE SAVINGS AND RISK AND EFFICACY IN COMPARATIVE ADVERTISING FOR PRESCRIPTION DRUGS
Jones, G.
• DECISION AIDS' EFFICACY TO SUPPORT WOMEN'S FERTILITY PRESERVATION CHOICES BEFORE CANCER TREATMENT: AN ENVIRONMENTAL SCAN

• WHAT FACTORS INFLUENCE THE FERTILITY PRESERVATION TREATMENT DECISION-MAKING PROCESS IN WOMEN WITH CANCER? THE QUALITATIVE FINDINGS OF THE PREFER STUDY
Jongen, P.
• A COMPARISON OF PATIENTS' AND HEALTHCARE PROFESSIONALS' PREFERENCES FOR THE CHARACTERISTICS OF DISEASE MODIFYING DRUGS IN DECISION MAKING ABOUT MULTIPLE SCLEROSIS TREATMENT
Joo, L.
• ASSOCIATION OF DEPRESSION WITH HOSPITAL LENGTH OF STAY AND 90-DAY READMISSION FOLLOWING TOTAL KNEE ARTHROPLASTY
Juanchich, M.
• ‘1-IN-X' RATIOS LEAD TO MEDICAL PROBABILITY OVERESTIMATION
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z